Origin Therapeutics Holdings Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORIG.CN research report →
Companywww.originpsychedelics.com
Origin Therapeutics Holdings Inc. , an investment issuer, primarily focuses on investments in the psychedelic industry in Canada. It plans to invests in the research, design, development, testing, production, distribution, and sale of psychedelics and related activities.
- CEO
- Michael Galego
- IPO
- 2022
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $1.41M
- P/E
- -0.60
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- 2.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.03%
- ROIC
- -10.30%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,340,296 · 0.00%
- EPS
- $-0.04 · 0.00%
- Op Income
- $-559,368
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.07
- 52W Low
- $0.00
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- 0.00
- Avg Volume
- 0
Get TickerSpark's AI analysis on ORIG.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ORIG.CN Coverage
We haven't published any research on ORIG.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ORIG.CN Report →